[FDA] not acting with scientific integrity; Senator Grassley

[Guest guest]

>

>

>

> " Senator Says F.D.A. Asked Canada Not to Suspend ADHD Drug

> Spotlight on Adderall "

>

>

> " The controversy . . . promises to engulf the F.D.A.

> in more questions about its oversight of the

> pharmaceutical industry. "

>

>

> [by Gardiner And Benedict Carey, NY times.]

> http://www.nytimes.com/2005/02/11/politics/11drug.html?

pagewanted=print & posi

> tion=

>

> A day after Canadian officials suspended the use of a

hyperactivity

> drug amid reports of deaths associated with its use, Senator

E.

> Grassley of Iowa contended that United States health officials had

asked the

> Canadian regulators not to do so.

> Senator Grassley, a Republican, said on Thursday that the

Food and

> Drug Administration had made the request of Canadian health

officials

> because the F.D.A. could not handle another " drug safety crisis. "

Mr.

> Grassley said he was basing his contentions on reports from

whistle-blowers

> within the agency.

> Dr. , director general of the therapeutic

products

> directorate at Health Canada, said through a spokeswoman that

reports that

> F.D.A. had asked Health Canada to refrain from suspending the

drug " are

> untrue. "

> Brad Stone, a spokesman for the F.D.A., declined to respond

directly

> to Mr. Grassley's contention but said of Dr. 's rejection

that, " We

> believe the Canadian response is the correct one. " Canadian health

> officials, citing 20 deaths among patients taking the British-made

drug

> Adderall XR, said on Wednesday night that they were suspending

sales of the

> hyperactivity drug indefinitely. The F.D.A. is allowing the drug

to continue

> to be sold in the United States, saying there is little evidence

that

> Adderall XR caused the deaths.

> Mr. Grassley, who has been investigating the Food and Drug

> Administration for about a year, demanded in a letter written on

Thursday

> that the agency answer questions about any discussions its

officials may

> have had with the Canadians about the drug.

> Dr. Temple, director of the F.D.A.'s office of

medical

> affairs,

> said the agency's decision to permit the continued sale of

Adderall was not

> influenced by the controversies swirling around the F.D.A.

> " It's still our job to get as close as we can to the right

answer and

> not panic and do things for the wrong reasons, " Dr. Temple said.

> Cabrey, a spokesman for the maker of Adderall, Shire

> Pharmaceuticals Group of Britain, said Adderall was safe and

effective. " We

> are very surprised at the actions of Health Canada, and we

disagree with

> their interpretations of the data around these extremely rare

cases of

> sudden death, " Mr. Cabrey said.

> The controversy - and the sudden appearance of Mr.

Grassley, the

> chairman of the Senate Finance Committee, in it - promises to

engulf the

> F.D.A. in more questions about its oversight of the pharmaceutical

industry.

> Critics have accused agency officials of being too cozy

with drug

> makers and of being slower than their counterparts in other

nations to

> acknowledge drug-safety problems.

> The controversy is also bound to fuel a long-running battle

over

> whether drugs like Adderall and Ritalin are overprescribed to

children, and

> whether the drugs' longterm risks have been adequately explored.

> More than 700,000 Americans use Adderall and its extended

release

> counterpart, Adderall XR. Shire sold $759 million of Adderall

products in

> the United States last year and $10 million in Canada.

> In the letter Thursday to the F.D.A., Mr. Grassley wrote

that reports

> given to his staff suggested that the agency was not acting with

scientific

> integrity.

> " Unfortunately, such allegations raise additional concerns

about the

> culture at the F.D.A., " he wrote.

> Dr. of Health Canada described discussions between

the two

> regulatory bodies as " collegial. "

> Differing health regulations govern the differing responses

of the

> two

> agencies to the Adderall reports, Dr. said. Canadian law

lets

> regulators suspend a drug's sales while safety questions are

investigated;

> United States law does not. Health Canada approved Shire's

application to

> sell Adderall XR in January 2004. In September, the company

reported to

> Canadian authorities that 20 people, 12 of them children, had died

suddenly

> in the United States while taking the drug.

> Shire asked the Canadian regulators for permission to

change the

> drug's label to reflect the possible dangers, as had been done in

the United

> States that month.

> Some of the deaths, which had not been previously reported

to

> Canadian

> authorities, occurred well before Health Canada approved Adderall

XR for

> sale, Dr. said.

> Canada and the United States both require pharmaceutical

companies to

> report all adverse outcomes from drugs promptly.

> " We were surprised to find these cases, " Dr. said

in an

> interview on Thursday.

> Dr. said that an early analysis of the data

suggested that

> Adderall XR might be linked to two to three times as many sudden

deaths as

> Ritalin and its cousin, Concerta, which are prescribed for similar

> disorders.

> Further, Dr. said that Canadian authorities were

uncertain

> about how to warn patients about the risks of sudden death.

> " It's very difficult to generate a benefit-to-risk balance

when the

> risk is sudden and unexpected death, " Dr. said.

> Mr. Cabrey of Shire Pharmaceuticals said that the company

had

> forwarded reports of the deaths to Canadian authorities promptly.

> Dr. Temple of the F.D.A. said that 7 children taking

Ritalin and

> Concerta died during the same period that 12 children taking

Adderall died,

> suggesting equivalent risks. Many had structural problems with

their hearts

> and several were engaged in vigorous exercise, he said.

> There is little evidence that the drugs caused any of the

deaths, he

> said. " There is a tendency to believe that sudden death doesn't

occur in

> children. That is wrong, " Dr. Temple said. He

added: " Psychiatrists say that

> these drugs are needed. To get rid of them for something that may

well be a

> background rate of death is not responsible. " Doctors have known

since the

> 1930's that stimulant medications like these can calm hyperactive,

or

> aggressive, children. But no one knows precisely how the drugs

induce this

> effect, and there have always been concerns about the drugs' long-

term

> effect on development.

> Prescriptions for these drugs to be used by children with

> attention-deficit disorder more than doubled in the 1990's,

experts say,

> heightening the concerns of some doctors.

> The drugs are far more popular in the United States than in

Europe.

> Last year, doctors in the United States wrote more than 23 million

> prescriptions for the four most popular drugs used to treat

attention

> deficit disorder.

>

> -- > DO SOMETHING ABOUT AUTISM NOW < --

>

> SUBSCRIBE. . . !

> . . .Read, then Forward the Schafer Autism Report.

> To Subscribe http://www.SARnet.org/

> Or mailto:subs@d... No Cost!

> _______________________________________________________

[Guest guest]

>

>

>

> " Senator Says F.D.A. Asked Canada Not to Suspend ADHD Drug

> Spotlight on Adderall "

>

>

> " The controversy . . . promises to engulf the F.D.A.

> in more questions about its oversight of the

> pharmaceutical industry. "

>

>

> [by Gardiner And Benedict Carey, NY times.]

> http://www.nytimes.com/2005/02/11/politics/11drug.html?

pagewanted=print & posi

> tion=

>

> A day after Canadian officials suspended the use of a

hyperactivity

> drug amid reports of deaths associated with its use, Senator

E.

> Grassley of Iowa contended that United States health officials had

asked the

> Canadian regulators not to do so.

> Senator Grassley, a Republican, said on Thursday that the

Food and

> Drug Administration had made the request of Canadian health

officials

> because the F.D.A. could not handle another " drug safety crisis. "

Mr.

> Grassley said he was basing his contentions on reports from

whistle-blowers

> within the agency.

> Dr. , director general of the therapeutic

products

> directorate at Health Canada, said through a spokeswoman that

reports that

> F.D.A. had asked Health Canada to refrain from suspending the

drug " are

> untrue. "

> Brad Stone, a spokesman for the F.D.A., declined to respond

directly

> to Mr. Grassley's contention but said of Dr. 's rejection

that, " We

> believe the Canadian response is the correct one. " Canadian health

> officials, citing 20 deaths among patients taking the British-made

drug

> Adderall XR, said on Wednesday night that they were suspending

sales of the

> hyperactivity drug indefinitely. The F.D.A. is allowing the drug

to continue

> to be sold in the United States, saying there is little evidence

that

> Adderall XR caused the deaths.

> Mr. Grassley, who has been investigating the Food and Drug

> Administration for about a year, demanded in a letter written on

Thursday

> that the agency answer questions about any discussions its

officials may

> have had with the Canadians about the drug.

> Dr. Temple, director of the F.D.A.'s office of

medical

> affairs,

> said the agency's decision to permit the continued sale of

Adderall was not

> influenced by the controversies swirling around the F.D.A.

> " It's still our job to get as close as we can to the right

answer and

> not panic and do things for the wrong reasons, " Dr. Temple said.

> Cabrey, a spokesman for the maker of Adderall, Shire

> Pharmaceuticals Group of Britain, said Adderall was safe and

effective. " We

> are very surprised at the actions of Health Canada, and we

disagree with

> their interpretations of the data around these extremely rare

cases of

> sudden death, " Mr. Cabrey said.

> The controversy - and the sudden appearance of Mr.

Grassley, the

> chairman of the Senate Finance Committee, in it - promises to

engulf the

> F.D.A. in more questions about its oversight of the pharmaceutical

industry.

> Critics have accused agency officials of being too cozy

with drug

> makers and of being slower than their counterparts in other

nations to

> acknowledge drug-safety problems.

> The controversy is also bound to fuel a long-running battle

over

> whether drugs like Adderall and Ritalin are overprescribed to

children, and

> whether the drugs' longterm risks have been adequately explored.

> More than 700,000 Americans use Adderall and its extended

release

> counterpart, Adderall XR. Shire sold $759 million of Adderall

products in

> the United States last year and $10 million in Canada.

> In the letter Thursday to the F.D.A., Mr. Grassley wrote

that reports

> given to his staff suggested that the agency was not acting with

scientific

> integrity.

> " Unfortunately, such allegations raise additional concerns

about the

> culture at the F.D.A., " he wrote.

> Dr. of Health Canada described discussions between

the two

> regulatory bodies as " collegial. "

> Differing health regulations govern the differing responses

of the

> two

> agencies to the Adderall reports, Dr. said. Canadian law

lets

> regulators suspend a drug's sales while safety questions are

investigated;

> United States law does not. Health Canada approved Shire's

application to

> sell Adderall XR in January 2004. In September, the company

reported to

> Canadian authorities that 20 people, 12 of them children, had died

suddenly

> in the United States while taking the drug.

> Shire asked the Canadian regulators for permission to

change the

> drug's label to reflect the possible dangers, as had been done in

the United

> States that month.

> Some of the deaths, which had not been previously reported

to

> Canadian

> authorities, occurred well before Health Canada approved Adderall

XR for

> sale, Dr. said.

> Canada and the United States both require pharmaceutical

companies to

> report all adverse outcomes from drugs promptly.

> " We were surprised to find these cases, " Dr. said

in an

> interview on Thursday.

> Dr. said that an early analysis of the data

suggested that

> Adderall XR might be linked to two to three times as many sudden

deaths as

> Ritalin and its cousin, Concerta, which are prescribed for similar

> disorders.

> Further, Dr. said that Canadian authorities were

uncertain

> about how to warn patients about the risks of sudden death.

> " It's very difficult to generate a benefit-to-risk balance

when the

> risk is sudden and unexpected death, " Dr. said.

> Mr. Cabrey of Shire Pharmaceuticals said that the company

had

> forwarded reports of the deaths to Canadian authorities promptly.

> Dr. Temple of the F.D.A. said that 7 children taking

Ritalin and

> Concerta died during the same period that 12 children taking

Adderall died,

> suggesting equivalent risks. Many had structural problems with

their hearts

> and several were engaged in vigorous exercise, he said.

> There is little evidence that the drugs caused any of the

deaths, he

> said. " There is a tendency to believe that sudden death doesn't

occur in

> children. That is wrong, " Dr. Temple said. He

added: " Psychiatrists say that

> these drugs are needed. To get rid of them for something that may

well be a

> background rate of death is not responsible. " Doctors have known

since the

> 1930's that stimulant medications like these can calm hyperactive,

or

> aggressive, children. But no one knows precisely how the drugs

induce this

> effect, and there have always been concerns about the drugs' long-

term

> effect on development.

> Prescriptions for these drugs to be used by children with

> attention-deficit disorder more than doubled in the 1990's,

experts say,

> heightening the concerns of some doctors.

> The drugs are far more popular in the United States than in

Europe.

> Last year, doctors in the United States wrote more than 23 million

> prescriptions for the four most popular drugs used to treat

attention

> deficit disorder.

>

> -- > DO SOMETHING ABOUT AUTISM NOW < --

>

> SUBSCRIBE. . . !

> . . .Read, then Forward the Schafer Autism Report.

> To Subscribe http://www.SARnet.org/

> Or mailto:subs@d... No Cost!

> _______________________________________________________

[Guest guest]

>

>

>

> " Senator Says F.D.A. Asked Canada Not to Suspend ADHD Drug

> Spotlight on Adderall "

>

>

> " The controversy . . . promises to engulf the F.D.A.

> in more questions about its oversight of the

> pharmaceutical industry. "

>

>

> [by Gardiner And Benedict Carey, NY times.]

> http://www.nytimes.com/2005/02/11/politics/11drug.html?

pagewanted=print & posi

> tion=

>

> A day after Canadian officials suspended the use of a

hyperactivity

> drug amid reports of deaths associated with its use, Senator

E.

> Grassley of Iowa contended that United States health officials had

asked the

> Canadian regulators not to do so.

> Senator Grassley, a Republican, said on Thursday that the

Food and

> Drug Administration had made the request of Canadian health

officials

> because the F.D.A. could not handle another " drug safety crisis. "

Mr.

> Grassley said he was basing his contentions on reports from

whistle-blowers

> within the agency.

> Dr. , director general of the therapeutic

products

> directorate at Health Canada, said through a spokeswoman that

reports that

> F.D.A. had asked Health Canada to refrain from suspending the

drug " are

> untrue. "

> Brad Stone, a spokesman for the F.D.A., declined to respond

directly

> to Mr. Grassley's contention but said of Dr. 's rejection

that, " We

> believe the Canadian response is the correct one. " Canadian health

> officials, citing 20 deaths among patients taking the British-made

drug

> Adderall XR, said on Wednesday night that they were suspending

sales of the

> hyperactivity drug indefinitely. The F.D.A. is allowing the drug

to continue

> to be sold in the United States, saying there is little evidence

that

> Adderall XR caused the deaths.

> Mr. Grassley, who has been investigating the Food and Drug

> Administration for about a year, demanded in a letter written on

Thursday

> that the agency answer questions about any discussions its

officials may

> have had with the Canadians about the drug.

> Dr. Temple, director of the F.D.A.'s office of

medical

> affairs,

> said the agency's decision to permit the continued sale of

Adderall was not

> influenced by the controversies swirling around the F.D.A.

> " It's still our job to get as close as we can to the right

answer and

> not panic and do things for the wrong reasons, " Dr. Temple said.

> Cabrey, a spokesman for the maker of Adderall, Shire

> Pharmaceuticals Group of Britain, said Adderall was safe and

effective. " We

> are very surprised at the actions of Health Canada, and we

disagree with

> their interpretations of the data around these extremely rare

cases of

> sudden death, " Mr. Cabrey said.

> The controversy - and the sudden appearance of Mr.

Grassley, the

> chairman of the Senate Finance Committee, in it - promises to

engulf the

> F.D.A. in more questions about its oversight of the pharmaceutical

industry.

> Critics have accused agency officials of being too cozy

with drug

> makers and of being slower than their counterparts in other

nations to

> acknowledge drug-safety problems.

> The controversy is also bound to fuel a long-running battle

over

> whether drugs like Adderall and Ritalin are overprescribed to

children, and

> whether the drugs' longterm risks have been adequately explored.

> More than 700,000 Americans use Adderall and its extended

release

> counterpart, Adderall XR. Shire sold $759 million of Adderall

products in

> the United States last year and $10 million in Canada.

> In the letter Thursday to the F.D.A., Mr. Grassley wrote

that reports

> given to his staff suggested that the agency was not acting with

scientific

> integrity.

> " Unfortunately, such allegations raise additional concerns

about the

> culture at the F.D.A., " he wrote.

> Dr. of Health Canada described discussions between

the two

> regulatory bodies as " collegial. "

> Differing health regulations govern the differing responses

of the

> two

> agencies to the Adderall reports, Dr. said. Canadian law

lets

> regulators suspend a drug's sales while safety questions are

investigated;

> United States law does not. Health Canada approved Shire's

application to

> sell Adderall XR in January 2004. In September, the company

reported to

> Canadian authorities that 20 people, 12 of them children, had died

suddenly

> in the United States while taking the drug.

> Shire asked the Canadian regulators for permission to

change the

> drug's label to reflect the possible dangers, as had been done in

the United

> States that month.

> Some of the deaths, which had not been previously reported

to

> Canadian

> authorities, occurred well before Health Canada approved Adderall

XR for

> sale, Dr. said.

> Canada and the United States both require pharmaceutical

companies to

> report all adverse outcomes from drugs promptly.

> " We were surprised to find these cases, " Dr. said

in an

> interview on Thursday.

> Dr. said that an early analysis of the data

suggested that

> Adderall XR might be linked to two to three times as many sudden

deaths as

> Ritalin and its cousin, Concerta, which are prescribed for similar

> disorders.

> Further, Dr. said that Canadian authorities were

uncertain

> about how to warn patients about the risks of sudden death.

> " It's very difficult to generate a benefit-to-risk balance

when the

> risk is sudden and unexpected death, " Dr. said.

> Mr. Cabrey of Shire Pharmaceuticals said that the company

had

> forwarded reports of the deaths to Canadian authorities promptly.

> Dr. Temple of the F.D.A. said that 7 children taking

Ritalin and

> Concerta died during the same period that 12 children taking

Adderall died,

> suggesting equivalent risks. Many had structural problems with

their hearts

> and several were engaged in vigorous exercise, he said.

> There is little evidence that the drugs caused any of the

deaths, he

> said. " There is a tendency to believe that sudden death doesn't

occur in

> children. That is wrong, " Dr. Temple said. He

added: " Psychiatrists say that

> these drugs are needed. To get rid of them for something that may

well be a

> background rate of death is not responsible. " Doctors have known

since the

> 1930's that stimulant medications like these can calm hyperactive,

or

> aggressive, children. But no one knows precisely how the drugs

induce this

> effect, and there have always been concerns about the drugs' long-

term

> effect on development.

> Prescriptions for these drugs to be used by children with

> attention-deficit disorder more than doubled in the 1990's,

experts say,

> heightening the concerns of some doctors.

> The drugs are far more popular in the United States than in

Europe.

> Last year, doctors in the United States wrote more than 23 million

> prescriptions for the four most popular drugs used to treat

attention

> deficit disorder.

>

> -- > DO SOMETHING ABOUT AUTISM NOW < --

>

> SUBSCRIBE. . . !

> . . .Read, then Forward the Schafer Autism Report.

> To Subscribe http://www.SARnet.org/

> Or mailto:subs@d... No Cost!

> _______________________________________________________

[Guest guest]

>

>

>

> " Senator Says F.D.A. Asked Canada Not to Suspend ADHD Drug

> Spotlight on Adderall "

>

>

> " The controversy . . . promises to engulf the F.D.A.

> in more questions about its oversight of the

> pharmaceutical industry. "

>

>

> [by Gardiner And Benedict Carey, NY times.]

> http://www.nytimes.com/2005/02/11/politics/11drug.html?

pagewanted=print & posi

> tion=

>

> A day after Canadian officials suspended the use of a

hyperactivity

> drug amid reports of deaths associated with its use, Senator

E.

> Grassley of Iowa contended that United States health officials had

asked the

> Canadian regulators not to do so.

> Senator Grassley, a Republican, said on Thursday that the

Food and

> Drug Administration had made the request of Canadian health

officials

> because the F.D.A. could not handle another " drug safety crisis. "

Mr.

> Grassley said he was basing his contentions on reports from

whistle-blowers

> within the agency.

> Dr. , director general of the therapeutic

products

> directorate at Health Canada, said through a spokeswoman that

reports that

> F.D.A. had asked Health Canada to refrain from suspending the

drug " are

> untrue. "

> Brad Stone, a spokesman for the F.D.A., declined to respond

directly

> to Mr. Grassley's contention but said of Dr. 's rejection

that, " We

> believe the Canadian response is the correct one. " Canadian health

> officials, citing 20 deaths among patients taking the British-made

drug

> Adderall XR, said on Wednesday night that they were suspending

sales of the

> hyperactivity drug indefinitely. The F.D.A. is allowing the drug

to continue

> to be sold in the United States, saying there is little evidence

that

> Adderall XR caused the deaths.

> Mr. Grassley, who has been investigating the Food and Drug

> Administration for about a year, demanded in a letter written on

Thursday

> that the agency answer questions about any discussions its

officials may

> have had with the Canadians about the drug.

> Dr. Temple, director of the F.D.A.'s office of

medical

> affairs,

> said the agency's decision to permit the continued sale of

Adderall was not

> influenced by the controversies swirling around the F.D.A.

> " It's still our job to get as close as we can to the right

answer and

> not panic and do things for the wrong reasons, " Dr. Temple said.

> Cabrey, a spokesman for the maker of Adderall, Shire

> Pharmaceuticals Group of Britain, said Adderall was safe and

effective. " We

> are very surprised at the actions of Health Canada, and we

disagree with

> their interpretations of the data around these extremely rare

cases of

> sudden death, " Mr. Cabrey said.

> The controversy - and the sudden appearance of Mr.

Grassley, the

> chairman of the Senate Finance Committee, in it - promises to

engulf the

> F.D.A. in more questions about its oversight of the pharmaceutical

industry.

> Critics have accused agency officials of being too cozy

with drug

> makers and of being slower than their counterparts in other

nations to

> acknowledge drug-safety problems.

> The controversy is also bound to fuel a long-running battle

over

> whether drugs like Adderall and Ritalin are overprescribed to

children, and

> whether the drugs' longterm risks have been adequately explored.

> More than 700,000 Americans use Adderall and its extended

release

> counterpart, Adderall XR. Shire sold $759 million of Adderall

products in

> the United States last year and $10 million in Canada.

> In the letter Thursday to the F.D.A., Mr. Grassley wrote

that reports

> given to his staff suggested that the agency was not acting with

scientific

> integrity.

> " Unfortunately, such allegations raise additional concerns

about the

> culture at the F.D.A., " he wrote.

> Dr. of Health Canada described discussions between

the two

> regulatory bodies as " collegial. "

> Differing health regulations govern the differing responses

of the

> two

> agencies to the Adderall reports, Dr. said. Canadian law

lets

> regulators suspend a drug's sales while safety questions are

investigated;

> United States law does not. Health Canada approved Shire's

application to

> sell Adderall XR in January 2004. In September, the company

reported to

> Canadian authorities that 20 people, 12 of them children, had died

suddenly

> in the United States while taking the drug.

> Shire asked the Canadian regulators for permission to

change the

> drug's label to reflect the possible dangers, as had been done in

the United

> States that month.

> Some of the deaths, which had not been previously reported

to

> Canadian

> authorities, occurred well before Health Canada approved Adderall

XR for

> sale, Dr. said.

> Canada and the United States both require pharmaceutical

companies to

> report all adverse outcomes from drugs promptly.

> " We were surprised to find these cases, " Dr. said

in an

> interview on Thursday.

> Dr. said that an early analysis of the data

suggested that

> Adderall XR might be linked to two to three times as many sudden

deaths as

> Ritalin and its cousin, Concerta, which are prescribed for similar

> disorders.

> Further, Dr. said that Canadian authorities were

uncertain

> about how to warn patients about the risks of sudden death.

> " It's very difficult to generate a benefit-to-risk balance

when the

> risk is sudden and unexpected death, " Dr. said.

> Mr. Cabrey of Shire Pharmaceuticals said that the company

had

> forwarded reports of the deaths to Canadian authorities promptly.

> Dr. Temple of the F.D.A. said that 7 children taking

Ritalin and

> Concerta died during the same period that 12 children taking

Adderall died,

> suggesting equivalent risks. Many had structural problems with

their hearts

> and several were engaged in vigorous exercise, he said.

> There is little evidence that the drugs caused any of the

deaths, he

> said. " There is a tendency to believe that sudden death doesn't

occur in

> children. That is wrong, " Dr. Temple said. He

added: " Psychiatrists say that

> these drugs are needed. To get rid of them for something that may

well be a

> background rate of death is not responsible. " Doctors have known

since the

> 1930's that stimulant medications like these can calm hyperactive,

or

> aggressive, children. But no one knows precisely how the drugs

induce this

> effect, and there have always been concerns about the drugs' long-

term

> effect on development.

> Prescriptions for these drugs to be used by children with

> attention-deficit disorder more than doubled in the 1990's,

experts say,

> heightening the concerns of some doctors.

> The drugs are far more popular in the United States than in

Europe.

> Last year, doctors in the United States wrote more than 23 million

> prescriptions for the four most popular drugs used to treat

attention

> deficit disorder.

>

> -- > DO SOMETHING ABOUT AUTISM NOW < --

>

> SUBSCRIBE. . . !

> . . .Read, then Forward the Schafer Autism Report.

> To Subscribe http://www.SARnet.org/

> Or mailto:subs@d... No Cost!

> _______________________________________________________